One dose of Novo Nordisk's Wegovy back in supply, FDA website shows-March 2024-www.financetom.com

One dose of Novo Nordisk's Wegovy back in supply, FDA website shows

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

One dose of Novo Nordisk's Wegovy back in supply, FDA website shows

Apr 29, 2024 9:10 AM

April 29 (Reuters) - The U.S. Food and Drug

Administration website showed on Monday one dose of Novo

Nordisk's weight-loss drug Wegovy is available after

being in short supply, while three other doses remained in

limited availability due to increased demand.

Previous page： Somnigroup International Q3 Adjusted Earnings, Net Sales Rise; 2025 Adjusted EPS Outlook Raised Next page： Moderna trims top end of full-year forecast on weak COVID vaccine sales

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Somnigroup International Q3 Adjusted Earnings, Net Sales Rise; 2025 Adjusted EPS Outlook Raised

Nov 6, 2025

07:11 AM EST, 11/06/2025 (MT Newswires) -- Somnigroup International ( SGI ) reported Q3 adjusted earnings Thursday of $0.95 per diluted share, up from $0.82 a year earlier. Analysts polled by FactSet expected $0.86. Net sales for the quarter ended Sept. 30 were $2.12 billion, up from $1.30 billion a year earlier. Analysts surveyed by FactSet expected $2.06 billion. The...

Moderna trims top end of full-year forecast on weak COVID vaccine sales

Nov 6, 2025

(Reuters) -Moderna ( MRNA ) lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots. The company said it now expects revenue of $1.6 billion to $2 billion for the year, down from its previous forecast of $1.5 billion...

Privia Health Q3 Non-GAAP Earnings, Revenue Rise; Raises 2025 Revenue Guidance

Nov 6, 2025

07:11 AM EST, 11/06/2025 (MT Newswires) -- Privia Health Group ( PRVA ) reported Q3 non-GAAP earnings Thursday of $0.29 per diluted share, up from $0.20 a year earlier. Analysts polled by FactSet expected $0.22. Revenue for the quarter ended Sept. 30 was $580.4 million, compared with $437.9 million a year earlier. Analysts surveyed by FactSet expected $492.7 million. For...

Papa John's Q3 revenue misses analyst estimates on weak US market, cuts FY foreast

Nov 6, 2025

Overview * Papa John's Q3 revenue flat yr/yr, missing analyst expectations * Adjusted EPS for Q3 misses analyst estimates * North America comparable sales down 3%, international sales up 7% Outlook * Company revises 2025 system-wide sales growth to 1% to 2% vs 2% to 2.5% earlier * North America comparable sales expected to decline 2% to 2.5% vs flat...